Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Operating Income

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-$4.62M-124%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$125.28M-2.4%

Segments

By segment

See full
Therapeutics Segment-$137.36M+5.6%

Other financials

Income statement

See full
Revenue-—
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.7B+54.2%
Enterprise value$3.35B+37.1%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s operating income?
Denali Therapeutics Inc. (DNLI) reported operating income of -$137.36M in Q1 2026.
How has Denali Therapeutics Inc.'s operating income changed year-over-year?
Denali Therapeutics Inc.'s operating income increased by 5.6% year-over-year, from -$145.58M to -$137.36M.
What is the long-term trend for Denali Therapeutics Inc.'s operating income?
Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s operating income has grown at a 17.1% compound annual growth rate (CAGR), from -$295.75M to -$555.34M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.